2024-09-15 - Analysis Report
##  PFE Stock Analysis

**Company Overview:** Pfizer Inc. (PFE) is a multinational pharmaceutical corporation that develops, manufactures, and distributes pharmaceuticals, vaccines, and consumer healthcare products. 

**Performance Summary:**

* **Rate of Return:** PFE has underperformed the S&P 500 (VOO) significantly, with a cumulative return of -26.43% compared to VOO's 87.74%. This results in a relative divergence of -114.17, which is within the bottom 2.89% of historical performance.
* **Recent Price Movement:** PFE's price is currently trading above its 5-day and 20-day moving averages, suggesting potential upward momentum. However, it is below the 60-day moving average, indicating a longer-term downtrend.
    * Closing Price: 29.16
    * 5-day moving average: 29.31
    * 20-day moving average: 28.87
    * 60-day moving average: 28.94
* **Technical Indicators:** 
    * **RSI:** 55.65, indicating a neutral market sentiment.
    * **PPO:** 0.35, suggesting potential bullish momentum.
    * **Delta_Previous_Relative_Divergence:** -3.4, indicating a short-term downward trend.
    * **Expected_Return:** 0.0%, indicating a potential for limited growth in the next five years.
* **Recent Earnings and Outlook:** PFE's recent earnings have been mixed. The company has exceeded analysts' expectations in the past two quarters (2024-07-30 and 2024-05-01), but missed expectations in the previous two quarters (2024-01-30 and 2023-10-31).
    * **Most Recent Earnings (2024-07-30):** EPS of 0.6, exceeding the estimated EPS of 0.458.

**Overall Analysis:**

PFE's performance has lagged significantly behind the S&P 500, indicating underperformance. The company's recent earnings have been mixed, showcasing a period of volatility. While technical indicators show some signs of bullish momentum, the long-term trend remains bearish. The expected return of 0.0% suggests limited potential for growth over the next five years. Investors considering PFE should carefully evaluate the company's future prospects, particularly in light of its dependence on its blockbuster drug Comirnaty (COVID-19 vaccine) and the potential for generic competition. 
